艾意凯：2023国际制药企业的中国市场机遇分析报告（英文版）（24页）.pdf

1、SPECIAL REPORTChina Market Opportunities for International PharmasAn extract from“Life Sciences Unicorns:From a China Investment Perspective”SPECIAL REPORTContents1.Introduction.32.Strategic Opportunities in China.43.MNC Pharmas:Adapting to the New Normal.74.New Entrants:Options&Trade-offs .165.Part

2、nership Considerations .196.Conclusion.21About the Author and the Book,in which the report was originally published.23About L.E.K.ConsultingWere L.E.K.Consulting,a global strategy consultancy working with business leaders to seize competitive advantage and amplify growth.Our insights are catalysts t

3、hat reshape the trajectory of our clients businesses,uncovering opportunities and empowering them to master their moments of truth.Since 1983,our worldwide practice spanning the Americas,Asia-Pacific and Europe has guided leaders across all industries from global corporations to emerging entrepreneu

4、rial businesses and private equity investors.Looking for more?Visit .L.E.K.Consulting is a registered trademark of L.E.K.Consulting LLC.All other products and brands mentioned in this document are properties of their respective owners.2023 L.E.K.Consulting LLC2 L.E.K.ConsultingSPECIAL REPORTChinas p

5、harmaceutical market presents an immense opportunity for pharmaceutical companies from home and abroad.With a vast population,significant unmet clinical needs,and a rapidly improving regulatory and market access environment,international pharmas have strategically expanded to China to invest in this

6、 dynamic market.Over the past four decades,these companies have made substantial investments,introduced hundreds of innovative medicines,and played a pivotal role in advancing the Chinese pharmaceutical industry.This L.E.K.Special Report explores the strategic opportunities available in China for in